Split-course radiation for diffuse midline glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new way of giving radiation therapy for a type of brain tumor called diffuse midline glioma. It aims to see if splitting the radiation into smaller courses can help while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 1 year old or older (any age welcome).
- You have a brain tumor called diffuse midline glioma that grows in the pons (a part of the brainstem) and affects at least half of it, seen on MRI.
- You must have at least one brainstem symptom like facial weakness, trouble walking, or arm/leg weakness.
- You are able to have an MRI of the brain.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and agree to use birth control.
- You and your caregiver speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a second course of radiation therapy to children and young adults with a type of brain tumor called diffuse midline glioma that has grown or come back after the first radiation. The goal is to see if re-irradiation can help control the tumor again.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This early-phase study tests a type of very targeted radiation given before surgery for people with a high-grade (aggressive) brain tumor. The goal is to see if this approach is safe and potentially improves treatment, while collecting tumor and blood samples for research.
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
This trial tests a combination of three drugs (temozolomide, anlotinib, and bemarituzumab) along with radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help shrink or control the tumor when surgery cannot remove it completely.
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.